Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies.

Polish archives of internal medicine - 29 Mar 2023

Jaroszewicz Jerzy, Zarębska-Michaluk Dorota, Janocha-Litwin Justyna, Parfieniuk-Kowerda Anna, Sitko Marek, Piekarska Anna, Białkowska Jolanta, Dybowska Dorota, Murawska-Ochab Aleksandra, Flisiak Robert

Abstract excerpt

INTRODUCTION: Despite the overall excellent efficacy of pangenotypic direct‑acting antiviral (DAA) options, there is still a small percentage of patients with hepatitis C virus (HCV) infection who do not respond to the therapy. OBJECTIVES: This analysis was designed to evaluate the effectiveness of pangenotypic retreatment in the cases of pangenotypic therapy failure. PATIENTS AND METHODS: The study included...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Retreatment

Share to Treatment Outcome

Source

Identifiers

PMID: 36602060
DOI: 10.20452/pamw.16400

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies.PMID 36602060Read ↗

Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.Semantic proximity Read ↗

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in TaiwanSemantic proximity Read ↗

Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antiviralsSemantic proximity Read ↗

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.Semantic proximity Read ↗

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.Semantic proximity Read ↗

Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.Semantic proximity Read ↗

High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosisSemantic proximity Read ↗

Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients.Semantic proximity Read ↗

Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study.Semantic proximity Read ↗

Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.Semantic proximity Read ↗

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.